{
 "as_of": "2026-11-06",
 "cmr": "se-cm-kg/XSTO/SE0008241491",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# SynAct Pharma AB (Nasdaq Stockholm: SE0008241491) — research page\n\nAs of 2026-11-06 · se-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is SynAct Pharma AB, listed on Nasdaq Stockholm, with ticker SE0008241491, ISIN SE0008241491 and LEI 549300RRYIEFEQ72N546. The security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 49 filings across 45 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 7.5 days. The median latency from the latest filing to the record date is 7.0 days for the exchange, against 2 days for this issuer. The exchange median is 9.5 days for cadence and 30.0 filings for the window, across 398 issuers. The sector median is not on the record. The latest filing is an Investor News item dated 2026-11-04.\n\n## Auditor\n\nThe auditor and its location are not on the record. Auditor changes are not on the record.\n\n## Events and halts\n\nThe listing, delisting, name change, domicile change and segment move lines are not on the record, because the index carries no lifecycle type map for this register. The halt flag is listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1.\n\n## Coverage\n\nTwo research houses are named on the issuer's investor-relations page: Edison Investment Research and BioVal BioStock Analytics.\n\n## Open research\n\nOne openly published research note is on the record: Edison Investment Research, dated 2025-10-28.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. No issuer years are sealed, and the market's earliest sealed date and the live record start date are not on the record.\n\n## Sources\n\n8 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://firds.esma.europa.eu/firds/ (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.se-cm-kg.ai/events/XSTO/SE0008241491 (the disclosure lines)\n- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)\n- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://www.synactpharma.com/en/investors/analysts/ (coverage)\n- https://www.edisongroup.com/research/differentiated-inflammation-resolution-approach/BM-2174/ (open research)\n- https://mcp.se-cm-kg.ai/record/XSTO/SE0008241491 (the record)\n",
 "market": "SE",
 "node": "se-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": null,
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "the SE vintage is not sealed; the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false
  },
  "auditor": {
   "auditor": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "SE",
    "state": "not_on_record"
   },
   "changes": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "se-cm-kg/XSTO/SE0008241491",
  "coverage": {
   "count": 2,
   "houses": [
    {
     "analyst": "Jyoti Prakash, CFA and Dr Arron Aatkar",
     "house": "Edison Investment Research",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "since": "2025-10-28",
     "source": "https://www.synactpharma.com/en/investors/analysts/",
     "state": "sourced"
    },
    {
     "analyst": "Hanna Norrlid, BioStock Analytics",
     "house": "BioVal BioStock Analytics",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "since": "2026-11-03",
     "source": "https://www.synactpharma.com/en/investors/analysts/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://www.synactpharma.com/en/investors/analysts/",
     "result": "read: 2 of 4 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": "stated per house where the page states it",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 398,
     "median_cadence_gap_days": 9.5,
     "median_filings": 30,
     "median_latency_days": 7,
     "name": "Nasdaq Stockholm"
    },
    "sector": {
     "market": "SE",
     "state": "not_on_record"
    }
   },
   "by_type": {
    "Annual Financial Report": 1,
    "Changes board/management/auditors": 2,
    "Changes in company's own shares": 2,
    "Decisions of general meeting": 2,
    "Financial Statement Release": 1,
    "Half Year financial report": 1,
    "Inside information": 5,
    "Interim report (Q1 and Q3)": 2,
    "Investor News": 28,
    "Notice to general meeting": 2,
    "Other information disclosed according to the rules of the Exchange": 2,
    "Total number of voting rights and capital": 1
   },
   "cadence_median_gap_days": 7.5,
   "filing_days": 45,
   "filings": 49,
   "latency_days": 2,
   "latest": [
    {
     "category": "Investor News",
     "date": "2026-11-04",
     "source": "https://view.news.eu.nasdaq.com/view?id=b22ad10672d641a45796afb099aa7e14b&lang=en&src=listed",
     "title": "SynAct Pharma announces attendance and presentation at upcoming investor conferences",
     "type": "Investor News"
    },
    {
     "category": "Interim report (Q1 and Q3)",
     "date": "2026-11-03",
     "source": "https://view.news.eu.nasdaq.com/view?id=bf6e72066797a388a9c8425fdf583d854&lang=en&src=listed",
     "title": "SynAct Pharma publishes Q3 2026 interim results",
     "type": "Interim report (Q1 and Q3)"
    },
    {
     "category": "Investor News",
     "date": "2026-11-03",
     "source": "https://view.news.eu.nasdaq.com/view?id=beaf18bf7f66cff4ce9eae7718340fa5c&lang=en&src=listed",
     "title": "SynAct Pharma announces initiation of coverage by BioVal BioStock Analytics",
     "type": "Investor News"
    },
    {
     "category": "Investor News",
     "date": "2026-10-27",
     "source": "https://view.news.eu.nasdaq.com/view?id=b81ee6bc1ffb227629b550e0d836fc20a&lang=en&src=listed",
     "title": "SynAct Pharma signs first commercial partnership for resomelagon with leading Brazilian pharmaceutical company",
     "type": "Investor News"
    },
    {
     "category": "Investor News",
     "date": "2026-09-22",
     "source": "https://view.news.eu.nasdaq.com/view?id=b3e9da56d3326b3815a7aa01538ef3374&lang=en&src=listed",
     "title": "SynAct Pharma to participate in investor and partnering conferences",
     "type": "Investor News"
    }
   ],
   "latest_filing_date": "2026-11-04",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.se-cm-kg.ai/events/XSTO/SE0008241491",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Nasdaq Stockholm"
   },
   "isin": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0008241491"
   },
   "jurisdiction": {
    "market": "SE",
    "state": "not_on_record"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-09",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN SE0008241491)",
    "state": "sourced",
    "value": "549300RRYIEFEQ72N546"
   },
   "name": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SynAct Pharma AB"
   },
   "sector": {
    "market": "SE",
    "state": "not_on_record"
   },
   "security_type": {
    "market": "SE",
    "state": "not_on_record"
   },
   "segment": {
    "market": "SE",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0008241491"
   },
   "website": {
    "market": "SE",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "SE",
  "node": "se-cm-kg",
  "numbers_hash": "sha256:444cfeff1939c2409da31a28955b9f3f4fa67120b08e0a0ff4f87ea516d118b8",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [
    {
     "date": "2025-10-28",
     "kind": "issuer-sponsored",
     "publisher": "Edison Investment Research",
     "read_by": "the note's own page, fetched by this rail",
     "read_date": "2026-11-12",
     "source": "https://www.edisongroup.com/research/differentiated-inflammation-resolution-approach/BM-2174/",
     "state": "sourced",
     "title": "SynAct Pharma – Differentiated inflammation resolution approach"
    }
   ],
   "state": "found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://se.eu-cm-kg.ai/book/aio.json",
    "door": "https://se.eu-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/se/mifid-ii-product-governance/r1",
   "section": "se.aio.v5"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.se-cm-kg.ai/record/XSTO/SE0008241491",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-09",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:444cfeff1939c2409da31a28955b9f3f4fa67120b08e0a0ff4f87ea516d118b8",
 "path": "/se/XSTO/SE0008241491",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is SynAct Pharma AB, listed on Nasdaq Stockholm, with ticker SE0008241491, ISIN SE0008241491 and LEI 549300RRYIEFEQ72N546. The security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 49 filings across 45 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 7.5 days. The median latency from the latest filing to the record date is 7.0 days for the exchange, against 2 days for this issuer. The exchange median is 9.5 days for cadence and 30.0 filings for the window, across 398 issuers. The sector median is not on the record. The latest filing is an Investor News item dated 2026-11-04.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor and its location are not on the record. Auditor changes are not on the record.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The listing, delisting, name change, domicile change and segment move lines are not on the record, because the index carries no lifecycle type map for this register. The halt flag is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "Two research houses are named on the issuer's investor-relations page: Edison Investment Research and BioVal BioStock Analytics.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "One openly published research note is on the record: Edison Investment Research, dated 2025-10-28.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The market's vintage is not sealed. No issuer years are sealed, and the market's earliest sealed date and the live record start date are not on the record.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "8 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://firds.esma.europa.eu/firds/"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.se-cm-kg.ai/events/XSTO/SE0008241491"
  },
  {
   "for": "the halt flag",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation"
  },
  {
   "for": "the orderability chapter",
   "source": "https://se.eu-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://www.synactpharma.com/en/investors/analysts/"
  },
  {
   "for": "open research",
   "source": "https://www.edisongroup.com/research/differentiated-inflammation-resolution-approach/BM-2174/"
  },
  {
   "for": "the record",
   "source": "https://mcp.se-cm-kg.ai/record/XSTO/SE0008241491"
  }
 ],
 "title": "SynAct Pharma AB (SE0008241491) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}